Print Page     Close Window     

SEC Filings

10-K
SERES THERAPEUTICS, INC. filed this Form 10-K on 03/16/2017
Entire Document
 

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common stock has been traded on The Nasdaq Global Select Market under the symbol “MCRB” since our initial public offering on June 26, 2015. Prior to this time, there was no public market for our common stock. The following table shows the high and low sale prices per share of our common stock as reported on The Nasdaq Global Select Market for the periods indicated:

 

 

 

High

 

 

Low

 

2016

 

 

 

 

 

 

 

 

First Quarter 2016

 

$

34.70

 

 

$

21.12

 

Second Quarter 2016

 

$

34.99

 

 

$

22.88

 

Third Quarter 2016

 

$

35.98

 

 

$

8.05

 

Fourth Quarter 2016

 

$

13.77

 

 

$

8.86

 

 

 

 

High

 

 

Low

 

2015

 

 

 

 

 

 

 

 

Second Quarter 2015 (beginning June 26, 2015)

 

$

51.40

 

 

$

28.11

 

Third Quarter 2015

 

$

52.00

 

 

$

26.95

 

Fourth Quarter 2015

 

$

44.51

 

 

$

25.00

 

 

On March 10, 2017, the last reported sale price for our common stock on The Nasdaq Global Select Market was $9.33 per share.

Stock Performance Graph

The graph set forth below compares the cumulative total stockholder return on our common stock between June 26, 2015 (the date of our initial public offering) and December 31, 2016, with the cumulative total return of (a) the Nasdaq Biotechnology Index and (b) the Nasdaq Composite Index, over the same period. This graph assumes the investment of $100 on June 26, 2015 in our common stock, the Nasdaq Biotechnology Index and the Nasdaq Composite Index and assumes the reinvestment of dividends, if any. The graph assumes our closing sales price on June 26, 2015 of $51.40 per share as the initial value of our common stock and not the initial offering price to the public of $18.00 per share.

 

 

Holders

As of March 10, 2017, there were approximately 23 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

65



© Seres Therapeutics. All Rights Reserved.